The Vertiflex™ Procedure†
Superion™ Indirect Decompression System
Talk with someone from our Health Economics and Market Access team. Discover ways you can identify appropriate candidates for the Vertiflex Procedure and support patient access to care.
Your Voice: Advocate for Access to Care
Patients afflicted with LSS face limited treatment options apart from surgical or conservative care. The Multispecialty Pain Workgroup (MPW) and state societies published position statements in support of indirect decompression procedures based upon Level 1–5 data for a well-defined patient population.1,2 In addition, the 2019 HHS Pain Management Best Practices Inter-Agency Task Force Report encourages use of non-fusion interspinous spacers for well selected patients.
The Vertiflex Procedure is the only FDA approved minimally invasive treatment clinically proven to treat pain symptoms associated with moderate LSS. The Vertiflex Procedure is supported by a 5-year Level 1 RCT and more than 30 peer-reviewed journal publications demonstrating durable efficacy and safety.
Most patients indicated for the Vertiflex Procedure have insurance coverage through original Medicare and a growing number of private health plans.3,4
The Boston Scientific Healthcare Economics and Market Access professionals can assist you and your office staff with navigating the insurance process and educating payers about spinal stenosis, alternative treatments, patient selection and outcomes. Contact our Experts.
Your engagement with local health plans is essential to ensure payers understand patient selection criteria and conditions for insurance coverage.
Take Action
- Speak with your patients about whether the Vertiflex Procedure could be an effective solution for their personal pain
- Connect with Boston Scientific Healthcare Economics and Market Access professionals for personalized support
- Actively engage and educate policymakers about LSS, appropriate patient selection and published outcomes unique to the Vertiflex Procedure